Deep-Tech Startups Support Program (DTSU) and Deep-Tech Startups Support Program in the Green Transformation field (GX)

Deep-Tech Startups Support Program (DTSU) and Deep-Tech Startups Support Program in the Green Transformation field (GX) is sponsored by New Energy and Industrial Technology Development Organization (NEDO) (Japan). This opportunity supports mission-aligned projects and measurable outcomes.

Deep-Tech Startups Support Program (DTSU), Deep-Tech Startups Support Program in the Green Transformation field (GX) | NEDO Deep-Tech Startups Support Program (DTSU), Deep-Tech Startups Support Program in the Green Transformation field (GX) Deep-Tech Startups Support Program (DTSU), Deep-Tech Startups Support Program in the Green Transformation field (GX) DTSU: Program period: FY2023 to FY2032, Total budget: JPY 87.

7billion (total for the entire project period) GX : Program period: FY2024 to FY2032, Total budget: JPY about 38 billion (as of April 2026) Overall picture of startups support programs in the deep-tech field "Deep-Tech Startups Support Program (DTSU)" and "Deep-Tech Startups Support Program in the Green Transformation field (GX)" provide support for research and development and commercialization in three phases for "deep-tech startups" engaged in research and development of innovative technologies.

Eligible projects are those that require long-term research and development and large-scale funding to establish the technology, commercialize it, and implement it in society and that are considered to contribute to solving economic and social issues (carbon neutrality, resource circulation, economic security, etc.) to be addressed by the country or the world as a whole, despite the high risk involved.

DTSU and GX : Aims and Measures DTSU and GX : Aims and Measures Program Flow, Program Period, NEDO's Contribution Rate, and Maximum subsidy Amount Maximum program period* (1) Up to four years for each phase. (One program period is the period until the next round of fundraising.)

Within 2/3 of the subsidy-eligible expenses 300 million yen or 500 million yen * (2) Total Up to 3 billion yen 500 million yen or 1 billion yen * (2) Within 2/3 of the subsidy-eligible expenses or 1/2 of the subsidy-eligible expenses * (3) *(1): The program period is set based on the period from the time when the business receives investment from VCs, CVCs, or other operating companies when it applies for this support program until the next time when the business plans receives investment from VCs, CVCs, or other operating companies (new fundraising).

Approximately 1. 5 to two years are standard. The maximum period in the above table can be set by going through the Stage-Gate (SG) reviewing process.

*(2): Conditions for subsidy increase: When the partner in the commercialization partnership is able to submit a statement of intent and a plan for overseas technology demonstrations *(3): Conditions for 1/2 contribution rate: When the ratio of the total amount of loans to the total amount of investments and loans in the DMP phase is 1/2 or more. (DTSU only. In GX, within 2/3.)

Each project can be continued in the same phase or the next phase if it is approved by the Stage-Gate review. Timing of Application and Stage-Gate Scheme Applications can be submitted from any phases. However, each proposer may apply for only one phase that best fits one’s company .

(To apply for a phase, the applicant is required to judge the suitability of the phase based on the most advanced business or research and development activities in one’s company). Public recruitment will be open for five years, from FY2023 to FY2027 . Timing of Application and Stage-Gate Scheme The support for each phase of the program is as follows.

・ Startups who start research and development and production of prototypes, and start marketing in the expected market, but have not yet fully realized a concrete product or service and are testing hypotheses for solving problems through research and development. ・ The standard is that, by the end of this phase, the product or service solves a specific problem for a specific target customer in the initial market.

・ Startups who aim to generate revenue by selecting appropriate initial and subsequent major markets (mainstream), solve the problems of target customers, and build business models as they further develop applications based on the results of such research and development, etc. ・ The standard is that, by the end of this phase, the product or service solves a problem for specific target customers in the initial market and major markets (mainstream) and meets the requirements for sustaining revenue.

・ Startups who aim to generate large revenues by selecting an appropriate major market (mainstream), solve the problems of the target customers, and build business models as they further develop applications based on the results of such research and development, etc. ・ However, to achieve this, it is necessary to establish a mass production system or conduct verification/demonstration related to business scaling.

・ The standard is that, by the end of this phase, the product or service solves a problem for specific target customers in the major market (mainstream), meets the requirements for starting commercial production, builds a business model that secures sustainable revenue, and is ready for actual mass production with the next round of funding.

・ Research and development of underlying technologies and development of prototypes ・ Implementation of feasibility studies to determine the direction of technology development for commercialization, etc. ・ Development of prototypes and initial production technology ・ Implementation of feasibility studies for the acquisition of major markets ・ Implementation of mass production demonstrations necessary for commercialization by designing, manufacturing, purchasing, introducing, and operating production and inspection equipment, etc., which are essential for research and development related to the establishment and demonstration of mass production technology.

2/3 or less or 1/2 or less * (3) 300 million yen or 500 million yen * (1) 500 million yen or 1 billion yen * (1) the open call guidelines) ・ The total amount of investment from one or more VCs, CVCs, or operating companies* (2) must be at least 1/3 or more of the subsidy-eligible expenses, and the investment must be made within a specified period* (4) . (DTSU only.)

・ Among these, the investors with the largest amount of shareholding ratio must be either VCs or CVCs. (DTSU only.) ・ The total amount of investment from one or more VCs, CVCs, or operating companies* (2) must be at least 1/3 or more of the subsidy-eligible expenses, and the investment must be made within a specified period* (4) .

(DTSU only.) ・ The VCs or CVCs must be included in the shareholder composition, or must be included within the specified period. ・ The total amount of investment from one or more VCs, CVCs, or operating companies* (2) and loans from financial institutions must be at least 1/3 or 1/2 of the subsidy-eligible expenses, and the investment must be made within the specified period* (4) .

(DTSU only.) ・ The VCs or CVCs must be included in the shareholder composition, or must be included within the specified period. ・ The applicant must submit a Memorandum of Understanding (MOU) with the partner regarding mass production demonstration, joint research, procurement, sales channel development, etc., for commercialization.

*(1): The maximum amount can be increased when the partner in the commercialization partnership is able to submit a letter of intent and a plan for overseas technological demonstrations.

*(2): Investments include convertible securities (convertible equity, convertible bonds, convertible notes, etc.) *(3): If the ratio of the total loan amount to the total investment and loan amount required to apply for the program is 1/2 or more, the subsidy rate will be reduced to 1/2 or less. (DTSU only. In GX, within 2/3.)

*(4): A period separately determined by NEDO based on the period from three months before the proposal deadline to one month after the date of the decision to adopt. ＜Adoption list in DTSU Program＞ R&D Cost of develops and provides "WPT" (wireless power transfer) technologies and solutions in Japan and overseas.

Accelerate creation of novel agrochemicals using molecularly targeted agrochemical platforms Development of global products for upper gastrointestinal endoscopic AI Research and development of production efficiency-enhancing edge AI solutions for the manufacturing industry Social Implementation of the Heart Sound AI Diagnostic Assistance System and Development of Heart Sound Biomarkers Development of Novel Phonocardiographic Digital Biomarkers and Establishment and Validation of Business Foundations in Key Markets Global deployment of surgical AI technology through optimization with next generation clinical devices Integration of surgical support AI technology with next-generation medical devices and global expansion Development of automation systems for assisted reproductive technologies Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy Demonstration of mass production for social implementation of the ASTERMOTOR drive system Advanced mass spectrometry sensors for real-time, automated control in semiconductor fabs Development of Fundamental Technology associated with Scalable AI Solutions for On-Site Productivity Improvement Development of VR Digital Therapeutics for Depression Technological Enhancements and Business Validation Toward International Development of Microbial Gene Database Research and development of cryptanalysis solutions using quantum computers Development of turbulence/wind prediction system through deep learning Boston Medical Sciences, Inc. Development of a non-invasive colorectal cancer screening system based on deep learning Boston Medical Sciences, Inc. Development of a non-invasive colorectal cancer screening system based on deep learning Development of exercise workload optimization function and cardiac rehabilitation program medical device Development and Global Expansion of a Remote Cardiac Rehabilitation Platform R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies GMP manufacturing of cells with CellFiberTM Technology CoreTissue BioEngineering, Inc Development of tissue-regenerated ligaments using decellularized biological tissues and their overseas expansion Globalization of Single Enzyme Activity-based Liquid Biopsy Crafton Biotechnology Inc. Development of a drug discovery system based on fully chemically synthesized mRNA Development of a materials platform for integrating internal and external data in the materials industry Development of a resource-recycling 3D printed construction method that revolutionizes productivity in silico enzyme libray development Development of Assisted Reproductive Technology Using Ovarian Cells Derived from iPS Cells Technological improvement and commercialization verification for international expansion of pig image recognition technology Demonstration for the multi-site development and large-scale utilization of fully organic superabsorbent polymers Development of High-Frequency Space Experimentation and Recovery Platform.

Realization of high-precision, high-speed machining of difficult-to-process materials by high-power laser processing machines Development of EV-Containing Medium that Significantly Increases the Success Rate of In Vitro Fertilization Microbial production of useful compounds by multistep gene introduction system Applied Research on Microbial Fermentative Production of Valuable Compounds through Multi-Step Metabolic Pathways Demonstration of low-cost mass production of high-performance α-Ga2O3 power semiconductors Development of innovative low-cost, high-quality mass production technique for gallium oxide substrates Development of a microsurgery assistance robot and a training system.

Construction of drug development platform of disease-specific degradation by CANDDY Construction of drug development platform of disease-specific degradation by CANDDY Launching a resource recycling business applying microalgae to precious metal recycling adsorbents. Global Vascular Co.

, Ltd. Development of a stent for the treatment of lower extremity artery disease, aimed at conducting clinical trials in Japan and obtaining regulatory approval in the U.S. Commercialization development of Gram staining automated AI medical device and overseas demonstration project Development of Semiconductor Advanced Packaging Inspection Equipment Horizon Illumination Lab Optics, Co.

Ltd. Technology Development for the Fundamental Innovation and Clinical Deployment of Opto-Diagnostics Establishment of a continuous synthesis system to accelerate practical application of complete solid solution Development of a microfactory using AI specialized in prosthetics and orthotics Integral Geometry Science, Inc. Research for mass-production of in-line battery inspection equipment of current density distribution Development and commercialization of a wireless implantable BMI Japan Superconductivity Application Development Inc. Development of Manufacturing Technology for Ultra-Fine Intermetallic Compounds Superconducting Wire with High Flexibility and Low AC Losses Research and development of base manufacturing towards commercialization of oral vaccine/feed additives for swine Demonstration development for mass production of oral vaccine/feed additive for swine Automation of Wind Turbine Blade repair robot Development of a small hybrid thruster for a small spacecraft Space demonstration of hybrid chemical propulsion using plastic as fuel Development of autonomous heavy transport robots for mixed-flow production in a human coexistence environment.

Liid Pharmaceuticals, Inc. Building the Oligonucleotide Safeguard Platform Business Development of the drug discovery platform based on 64Cu to expedite the R&D of new-generation drugs Development of a high-purity lithium extraction technology from solid material Commercialization of synthetic biology platform R&D Cost for the Development of an Autonomous Driving Robot for Fully Automating Short-Distance Transport of Goods and People Development of long-distance quantum communication system and market creation Development and Validation of Quantum Repeater Systems for Advanced Cryptography and Information Processing Development of flexible-arm photoacoustic imaging system Developing foundational technologies for Manga Machine Translation Innovative medical device based on contactless bioinformation measurement using mmwave radar Development of Next-Generation Artificial Knee Joint and AI Surgical Assistance for Innovative Treatment Development of small, low-cost Doppler LiDARs and accuracy verification methods for mass production.

Development of MylcMAT products using immortalized monocytic cells aMylc Development of MylcEndo products for the LAL market using immortalized monocytic cells aMylc-Z Development of mass-produced hybrid rocket system Creation of a Japanese materials industry through mass production and overseas expansion of silkworm biomaterials Development of an Innovative Anti-Thrombotic Coated Stent for Intracranial Aneurysm Treatment Nanofiber Quantum Technologies, Inc. Development of quantum repeater utilizing cavity QED Development of innovative EV component design environment utilizing metamaterials Research and development of production technology for recycled coal ash fiber Development of plant factory technology and validation of business model to realize sustainable agriculture Establishment of mass production technology for a propulsion system using water as a propellant for artificial satellites.

Physiologas Technologies Inc. Research and development of cryptanalysis solutions using quantum computers Phytolipid Technologies Co.

, Ltd. Business Demonstration of a Valuable Lipid Production Project Maximizing the Characteristics of a High Lipid-Producing Microalga Development of a Behavior Modification System Using Minimally/Non-Invasive Weekly Average Blood Glucose Monitoring for Home Use International Expansion of Wearable Epileptic Seizure Detection Systems Rapyuta Robotics Company Limited Development to expand the introduction of picking and storage solutions into warehouses Red Arrow Therapeutics, K.

K.

Development of pH-sensitive polymers as an inovative platform for protein delivery Regional Fish Institute, Ltd. Development of high-quality aquatic product species adapted to global boiling conditions R&D of a large-scale automated warehouse system utilizing optimized fleet control for resolving the logistics crisis AI-based Thermal-Fluid Simulation Leading to Automated Product Design Development of an Innovative Stent Graft System for Aortic Aneurysms in the Arch Project to develop a domestic surgical robot with pneumatic-driven force sensing function for the U.S. market Creation of Delicious Next-Generation Aquaculture Fish Adapted to Global Warming Research and development for practical application of next-generation focused ultrasound therapy system for refractory cancer Development of Mass Production Technology for Short-Wavelength Picosecond Laser Oscillators Development of a Versatile AI Neuroimaging Technology to Optimize Dementia Diagnosis Commercialization of a device for the treatment of acute ischemic stroke due to atherosclerosis.

Next-Generation Molecular Structure Analysis Platform Enabled by Innovative MOFs Mass production verification of ultra-high energy and ultra-high power density lithium-ion batteries Demonstration of mass production of an AI-based high-throughput cell analysis and sorting system R&D of “Self-learning robot hand” Development of software-embedded electrification modules for autonomous driving R&D of a new immersive solid-phase synthesis method Realization of Variable-Volume and Variable-Type Production through Flexible Fabrication Using AMR Development of an AI Foundation Model for Achieving Fully Autonomous Driving Development of an inspection AI robot to solve social infrastructure maintenance issues United Immunity Co.

, Ltd. Development of drug delivery capsule that selectively delivers mRNA et al. to immune cells Development of a mass production-ready "Small-scale, decentralised water recycling system for residential use" xFOREST Therapeutics Co.

, Ltd. Development of Hit to Lead Platform to Accelerate RNA-Targeted Small Molecule Drug Discovery Development of micro-architected gas diffusion layer for electrolysis with high output and low cost ＜Adoption list in GX Program＞ Development of an ultra-high-transmittance, highly durable EUV pellicle using multi-layer graphene Waterless Textile Colouration Mass Production Demonstration of Equipment and Materials for Multilayer Printed Circuit Boards (PCBs) Using Nano Copper Inkjet Printing Development of a Microbial Wastewater Treatment System for High-Capacity, Oil-Containing Effluents Contributing to Decarbonization Development to expand the introduction of picking and storage solutions into warehouses Demonstration project for industrial production technology of non-edible biomass-derived resin Development of high-power, continuously operating millimeter-wave generator and its application to deep geothermal heat, etc. Development of practical Single Molecule Electret (SME) memory for low-power computers R&D Cost of mii-Bioprocess Development of an operational network optimisation system to decarbonise aviation Development and Demonstration of a Compact and High-Efficiency Carbon Dioxide Capture System Using Membranes R&D of high-efficiency atmospheric CO 2 enrichment system for practical use of DACCU Topological AFRAM Development R&D Cost of Decarbonization-Promoting Product Development and Scaled Production in the Aquaculture Industry Development of Functional Conducting Additive Using Innovative Carbon Material GMS Development of Functional Conducting Additive Using Innovative Carbon Material GMS Adoption Status of DTSU(1st-8th Round) 【111 companies (STS:55 PCA:42 DMP:14)】 Adoption Status of GX（1st-5th Round) 【16 companies (STS:11 PCA:4 DMP:1)】 Cross-sectoral proposal-based programs Startup Support Department ( E-MAIL: dtsu[*]nedo.

go. jp ) To send an inquiry by E-mail, please replace [*] with @ in the above email addresses. Last Updated : April 21, 2026